2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Regulatory Challenges: Navigating the approval process for new therapies.
Navigating the approval process for new cancer therapies presents a significant regulatory challenge, one that demands a careful balance between scientific innovation and patient safety. The approval journey begins with preclinical studies that test the therapy's basic efficacy and safety, followed by a series of clinical trials that involve human participants. Each stage must meet stringent standards set by regulatory agencies, such as the FDA in the U.S. or the EMA in Europe, which require robust data demonstrating that a therapy is both effective and free from harmful side effects. The process can take years, during which researchers must continually monitor patient safety and submit comprehensive reports. Additionally, varying regulatory requirements across different regions may delay or complicate the approval process, requiring cross-border collaboration to ensure that promising new therapies can be used globally. Successful navigation of these challenges is crucial for bringing innovative cancer treatments to patients in need.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China